Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine-Reference-Cited by-同舟云学术

Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine

Published:2021-04-16 Issue:7 Volume:39 Page:771-788
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Vellekoop Heleen^ORCID,Huygens Simone^ORCID,Versteegh Matthijs^ORCID,Szilberhorn László^ORCID,Zelei Tamás^ORCID,Nagy Balázs^ORCID,Koleva-Kolarova Rositsa^ORCID,Tsiachristas Apostolos^ORCID,Wordsworth Sarah^ORCID,Rutten-van Mölken Maureen^ORCID,

Funder

Horizon 2020

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-021-01010-z.pdf

Reference80 articles.

1. D’Andrea E, Marzuillo C, Pelone F, et al. Genetic testing and economic evaluations: a systematic review of the literature. Epidemiol Prev. 2015;39:45–50.

2. Wright SJ, Newman WG, Payne K. Accounting for capacity constraints in economic evaluations of precision medicine: a systematic review. Pharmacoeconomics. 2019;37:1011–27.

3. Hatz MH, Schremser K, Rogowski WH. Is individualized medicine more cost-effective? A systematic review. Pharmacoeconomics. 2014;32:443–55.

4. Plothner M, Ribbentrop D, Hartman JP, et al. Cost-effectiveness of pharmacogenomic and pharmacogenetic test-guided personalized therapies: a systematic review of the approved active substances for personalized medicine in Germany. Adv Ther. 2016;33:1461–80.

5. Ferkol T, Quinton P. Precision medicine: at what price? Am J Respir Crit Care Med. 2015;192:658–9.

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scenario analysis and multi-criteria decision analysis to explore alternative reimbursement pathways for whole genome sequencing for blood cancer patients;Journal of Cancer Policy;2024-09

2. A Review of Cold-Wet Mizaj and Phlegm Dominance Indices in Persian Medicine;Shiraz E-Medical Journal;2024-06-22

3. Discrete Event Simulation to Incorporate Infusion Wait-Time When Assessing Cost-Effectiveness of a Chimeric-Antigen Receptor T Cell Therapy;Value in Health;2024-04

4. Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling;PharmacoEconomics;2024-03-18

5. Developments and future prospects of personalized medicine in head and neck squamous cell carcinoma diagnoses and treatments;Cancer Reports;2024-03